These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 4876979

  • 1. Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice.
    Fefer A, McCoy JL, Perk K, Glynn JP.
    Cancer Res; 1968 Aug; 28(8):1577-85. PubMed ID: 4876979
    [No Abstract] [Full Text] [Related]

  • 2. Induction and regression of primary moloney sarcoma virus-induced tumors in mice.
    Fefer A, McCoy JL, Glynn JP.
    Cancer Res; 1967 Sep; 27(9):1626-31. PubMed ID: 4860892
    [No Abstract] [Full Text] [Related]

  • 3. Increased oncogenicity of the murine sarcoma virus (Moloney) by co-infection with murine leukemia viruses.
    Chirigos MA, Perk K, Turner W, Burka B, Gomez M.
    Cancer Res; 1968 Jun; 28(6):1055-63. PubMed ID: 5658439
    [No Abstract] [Full Text] [Related]

  • 4. Studies on immunity to autochthonous mouse tumors.
    Hellström I, Hellström KE, Pierce GE, Fefer A.
    Transplant Proc; 1969 Mar; 1(1):90-4. PubMed ID: 5406848
    [No Abstract] [Full Text] [Related]

  • 5. Serochemotherapy against a Moloney virus-induced leukemia.
    Pearson GR, Redmon LW, Pearson JW.
    Cancer Res; 1973 Aug; 33(8):1854-7. PubMed ID: 4578564
    [No Abstract] [Full Text] [Related]

  • 6. Antibody production and interaction with lymphoid cells in relation to tumor immunity in the Moloney sarcoma virus system.
    Harada M, Pearson G, Redmon L, Winters E, Kasuga S.
    J Immunol; 1975 Apr; 114(4):1318-22. PubMed ID: 1090675
    [Abstract] [Full Text] [Related]

  • 7. Immunological and pathological manifestations of murine sarcoma virus (Moloney) infections.
    Schlom J, Moloney JB, Groupé V.
    Cancer Res; 1970 Dec; 30(12):2955-61. PubMed ID: 5494580
    [No Abstract] [Full Text] [Related]

  • 8. [Transplantable ascitic tumor derived from a mouse with moloney sarcoma: tumorigenic, antigenic and virologic properties (author's transl)].
    Weiland E, Weiland F.
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):151-61. PubMed ID: 4283271
    [No Abstract] [Full Text] [Related]

  • 9. Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma.
    Pearson GR, Redmon LW, Bass LR.
    Cancer Res; 1973 Jan; 33(1):171-8. PubMed ID: 4734119
    [No Abstract] [Full Text] [Related]

  • 10. Interference of daunomycin and adriamycin on the growth and aggression of murine sarcoma virus (Moloney) tumors in mice.
    Casazza M, Di Marco A, Di Cuonzo G.
    Cancer Res; 1971 Dec; 31(12):1971-6. PubMed ID: 5120294
    [No Abstract] [Full Text] [Related]

  • 11. Studies on the growth and regression of a transplantable Moloney sarcoma.
    Fefer A, McCoy JL, Glynn JP.
    Cancer Res; 1967 Nov; 27(11):2207-11. PubMed ID: 4864248
    [No Abstract] [Full Text] [Related]

  • 12. [Factors regulating the spontaneous regression of primary tumors induced by murine sarcoma virus, Moloney strain, in mice (BALB-c-Cb-Se). I. Age at treatment and virus doses].
    Ribacchi R, Giraldo G.
    Lav Ist Anat Istol Patol Univ Studi Perugia; 1967 Nov; 27(3):167-76. PubMed ID: 5605880
    [No Abstract] [Full Text] [Related]

  • 13. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.
    Fefer A.
    Cancer Res; 1969 Dec; 29(12):2177-83. PubMed ID: 5369675
    [No Abstract] [Full Text] [Related]

  • 14. Tumor specific antigens in viral neoplasms and in unrelated virus infected tumors.
    Sjögren HO.
    Ann Med Exp Biol Fenn; 1966 Dec; 44(2):227-31. PubMed ID: 4290659
    [No Abstract] [Full Text] [Related]

  • 15. Antigenicity of a virus-induced murine sarcoma (Moloney).
    Fefer A, McCoy JL, Glynn JP.
    Cancer Res; 1967 May; 27(5):962-7. PubMed ID: 4290556
    [No Abstract] [Full Text] [Related]

  • 16. The immune response to primary Moloney sarcoma virus tumors in BALB-c mice: cellular and humoral activity of long-term regressors.
    Lamon EW, Anderson B, Wigzell H, Fenyö EM, Klein E.
    Int J Cancer; 1974 Jan 15; 13(1):91-104. PubMed ID: 4594340
    [No Abstract] [Full Text] [Related]

  • 17. Enhancement of normal lymphocyte cytotoxicity by sera with high antibody titers against H-2 or virus-associated antigens.
    Harada M, Pearson G, Pettigrew H, Redmon L, Orr T.
    Cancer Res; 1973 Nov 15; 33(11):2886-93. PubMed ID: 4583975
    [No Abstract] [Full Text] [Related]

  • 18. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D, Ronchese F, Zanovello P, Biasi G, Chieco-Bianchi L.
    J Immunol; 1982 Feb 15; 128(2):774-9. PubMed ID: 6459385
    [No Abstract] [Full Text] [Related]

  • 19. Senescent loss of resistance to murine sarcoma virus (Moloney) in the mouse.
    Pazmiño NH, Yuhas JM.
    Cancer Res; 1973 Nov 15; 33(11):2668-72. PubMed ID: 4748428
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.